ASX Health Stocks: Global Health nabs Fujitsu contract, Althea generates $5.3m after property deal

Digital health solution provider Global Health rose more than 6 per cent on Monday after announcing a strategic reseller agreement with Fujitsu Australia.

Global Health and Fujitsu have struck a deal. Picture: iStock

Global Health (ASX:GLH), a provider of digital health solutions, rose more than 6 per cent on Monday after announcing a strategic reseller agreement with Fujitsu Australia.

Under the deal, Fujitsu will promote, sell and implement GLH’s products and support services to the healthcare industry across 13 countries within the Asia Pacific region.

---

For the latest health news, sign up here for free Stockhead daily newsletters

---

The agreement covers the full suite of GLH’s complete platforms including the MasterCare suite of electronic medical records for hospitals, Patient Administration, and HotHealth for online engagement between healthcare providers and their patients.

GLH says the agreement is in line with its strategy to work with resellers that have a strong presence in the multiple jurisdictions that are seeking to digitise healthcare.

Global Health believes it can leverage the scale and expertise of Fujitsu, a global company with capabilities and access to new markets and geographies.

The company says this partnership will help accelerate market growth, while also allowing it to maintain a constant focus on improving its software solutions.

“Together, this strategic relationship will empower customers to improve patient experience, enhance workforce satisfaction and boost population health more cost-effectively,” said Global Health CEO, Mathew Cherian.

At 2.30pm Monday (AEDT), GLH was up 6.25 per cent for the day.

---

MORE FROM STOCKHEAD: Big win for cannabis| Arovella’s world-first cancer therapy | Kazia exits ASX

---

Althea generates $5.32m on property deal

Cannabis company Althea Group (ASX:AGH) has generated $C4.6 million (about $A5.32 million) after a sale and leaseback agreement on its land and building assets in Ontario.

The leaseback with a private investor in Canada has secured a term of up to 15 years.

The property was bought by AGH in 2019 for $2.6 million, and is home to the company’s wholly-owned subsidiary, Peak Processing Solutions, a Health Canada-licensed contract manufacturer of adult-use cannabis products.

Althea says the funds received will be used to repay the entirety of AGH’s debt, including full repayment and redemption of all outstanding convertible notes.

Following these repayments, the company’s balance sheet will be substantially strengthened, with the net proceeds of the transaction of approx. $1.2 million adding to the September 30 cash balance, for a total of $4.8 million.

At 2.30pm Monday (AEDT), AGH was up more than 8 per cent for the day.

---

Visit Stockhead, where ASX small caps are big deals

---

Immutep to present data at ESMO Congress

Immutep (ASX:IMM) says new updated data from its TACTI-002 trial, including more mature Overall Survival data, will be presented during the ESMO Congress in Madrid this Saturday, October 21.

TACTI-002 is a Phase 2 trial evaluating the chemotherapy-free combination of eftilagimod alpha (efti) and KEYTRUDA (pembrolizumab), Merck & Co’s anti-PD-1 therapy, in 1L NSCLC (non-small cell lung cancer).

Immutep says the TACTI-002 abstract will show an excellent initial survival benefit across an all patient population in NSCLC, as well as for patients in each PD-L1 Tumour Proportion Score (TPS) subgroup.

Notably, the new updated data from TACTI-002 will include more mature Overall Survival results.

Abstracts are available on the ESMO website, and the mini oral presentation and posters will be available on Immutep’s website following the presentation.

This content first appeared on stockhead.com.au

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox. Click here

Originally published as ASX Health Stocks: Global Health nabs Fujitsu contract, Althea generates $5.3m after property deal